Maxim Group Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX)

Equities researchers at Maxim Group assumed coverage on shares of Quince Therapeutics (NASDAQ:QNCX) in a research note issued to investors on Thursday, Benzinga reports. The firm set a “buy” rating and a $6.00 price target on the stock. Maxim Group’s price target points to a potential upside of 310.96% from the stock’s current price.

Several other equities analysts have also recently issued reports on the company. Rodman & Renshaw assumed coverage on Quince Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $11.00 target price on the stock. EF Hutton Acquisition Co. I upgraded Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 22nd. Finally, RODMAN&RENSHAW upgraded Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 29th.

Quince Therapeutics Stock Performance

Shares of QNCX stock opened at $1.46 on Thursday. The stock has a market capitalization of $63.19 million, a PE ratio of -1.16 and a beta of 0.71. Quince Therapeutics has a 52-week low of $0.51 and a 52-week high of $1.79. The stock’s 50-day moving average price is $0.87 and its 200 day moving average price is $0.82. The company has a quick ratio of 6.15, a current ratio of 6.15 and a debt-to-equity ratio of 0.29.

Quince Therapeutics (NASDAQ:QNCX) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter.

Insider Transactions at Quince Therapeutics

In other news, President Charles S. Ryan purchased 48,387 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were acquired at an average price of $0.65 per share, with a total value of $31,451.55. Following the purchase, the president now directly owns 122,461 shares of the company’s stock, valued at $79,599.65. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. In related news, President Charles S. Ryan bought 48,387 shares of Quince Therapeutics stock in a transaction that occurred on Tuesday, August 20th. The shares were purchased at an average price of $0.65 per share, with a total value of $31,451.55. Following the purchase, the president now owns 122,461 shares in the company, valued at $79,599.65. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Dirk Thye bought 77,500 shares of Quince Therapeutics stock in a transaction that occurred on Thursday, August 29th. The stock was bought at an average cost of $0.69 per share, for a total transaction of $53,475.00. Following the purchase, the chief executive officer now owns 766,941 shares in the company, valued at $529,189.29. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought 158,887 shares of company stock valued at $105,609 in the last quarter. 16.80% of the stock is currently owned by corporate insiders.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.